Eli Lilly's (LLY) popular weight-loss drug Zepbound outperformed Wegovy, a competitor drug from Danish drugmaker Novo Nordisk (NVO), according to the results of a🔯ꦛ new clinical study released Wednesday.

In a randomized study sponsored by the Zepbound maker that involved 751 patients across the U.S., patients taking Zepbound lost an average 20.2% of their body weight compared with 13.7% by those taking Wegovy over the course of a 72-week trial.

That translates to an average roughly 50-pound loss for patients on Zepbound versus about 33 pounds lost on Wegovy, Eli Lilly said Wednesday.

"Given the increased interest around obesity medications, we conducted this study to help health care providers and patients make informed decisions about treatment choice," said Lilly's SVP of Global Medical Affairs, Leonard Glass. "We are thrilled that today's findings showed the superior weight loss of Zepbound, which helped patients achieve 47% more relative weight loss compared to Wegovy."

Study 🎃Mirrors Similar Trial Results P❀ublished in July

The latest result mirrors another, 澳洲幸运5官方开奖结果体彩网:larger study published over the summer, whicಞh showed tirzepatide, the active ingredient in Eli Lilly's weight-loss drugs, caused more weight decline at a faster pace than Novo Nordisk's semaglutide.

The popularity of the weight-loss drugs has 澳洲幸运5官方开奖结果体彩网:boosted Eli Lilly's and 澳洲幸运5官方开奖结果体彩网:Novo Nordisk's sales and the companies' share prices over the last year. After 澳洲幸运5官方开奖结果体彩网:declining from record highs following recent 澳洲幸运5官方开奖结果体彩网:earnings reports, the drug makers' stocks each were propelled higher last month on the news that the 澳洲幸运5官方开奖结果体꧂彩网:Biden administration proposed cove♕ring the drugs 澳洲幸运5官方开奖结果体彩网:through Medicare and Medicaid to treat obesity and the sub𒁏sequent health problems it can cause.

Eli Lilly shares were up more than 3% Wednesday, while Novo Nordisk's U.S.-listed shares were up about 0.8%. Lilly shares are up 43% on the year, while Novo Nordisk is just 6% above the price at which it started trading at the beginning of 2024.